Evidence map›Paper›PMID 42359325›Full record

ReviewFrontiers in surgery2026

Radiofrequency ablation of papillary thyroid microcarcinoma.

Alessandro Serblin, Roberto Valcavi

Abstract readReview
In one paragraph

Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alessandro SerblinThe Endocrine and Thyroid Clinic, Reggio Emilia, Italy.
Roberto ValcaviThe Endocrine and Thyroid Clinic, Reggio Emilia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary thyroid microcarcinoma (PTMC), defined as papillary thyroid carcinoma measuring ≤1 cm, has emerged as a distinct clinical entity with a generally indolent course. The optimal management of PTMC remains controversial, with three main strategies currently adopted: surgical resection, active surveillance, and image-guided thermal ablation ( 16). This review provides a comprehensive analysis of these approaches, emphasizing their indications, outcomes, and limitations. Conventional surgery remains the gold standard, ensuring complete tumor excision but often associated with overtreatment, postoperative complications, and quality-of-life impairment. Active surveillance has gained acceptance as a conservative option for low-risk PTMC, reducing unnecessary interventions yet requiring long-term follow-up and patient compliance. Among minimally invasive alternatives, radiofrequency ablation (RFA) has shown growing evidence as a safe and effective technique for selected patients, achieving local tumor control with minimal morbidity and favorable cosmetic results. The review critically compares the efficacy, safety profiles, and patient selection criteria across these management modalities, highlighting the role of RFA as an emerging therapeutic tool that bridges the gap between surgical and observational strategies in the individualized treatment of PTMC.

Indexed as

active surveillance (AS)flexible fiberoptic laryngoscopy (FFL)papillary thyroid microcarcinoma (PTMC)radiofrequency ablation (RFA)surgerythyroid

Identifiers

PMID42359325
PMCPMC13290439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.